Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisplatin and Metronomic Cyclophosphamide in Metastatic TNBC
NCT01910870Phase 2Terminated
- Sponsor
- Centre Jean Perrin
- Start
- Jul 2013
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin and cyclophosphamide in triple negative breast cancer (TNBC), sponsored by Centre Jean Perrin. Primary endpoint: Response Rate at 6 weeks. Started Jul 2013; status: terminated.
02
Drugs
cisplatincyclophosphamide
03
Conditions
triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01910870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01910870.